JAZZ - Jazz Pharmaceuticals Non-GAAP EPS of $3.73 misses by $0.16 revenue of $813.72M misses by $40.01M; raises FY22 guidance

Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q1 Non-GAAP EPS of $3.73 misses by $0.16. Revenue of $813.72M (+33.9% Y/Y) misses by $40.01M. The Company is raising its full year 2022 financial guidance as follows: Revenues of $3,500M - $3,700M (prior $3,460M - $3,660M) vs. consensus of $3.58B ; GAAP Net income per diluted share of $0.25 - $3.20 (prior $0.50 - $3.00) and Non-GAAP Net income per diluted share of $16.70 - $17.70 (prior $16.00 - $17.00) vs. consensus of $16.60.

For further details see:

Jazz Pharmaceuticals Non-GAAP EPS of $3.73 misses by $0.16, revenue of $813.72M misses by $40.01M; raises FY22 guidance